An unresolved issue in rhabdomyosarcoma treatment: The duration of chemotherapy

被引：9

作者：

Bisogno, Gianni ^{[1
]}

Hawkins, Douglas S. ^{[2
]}

机构：

[1] Univ Padua, Dept Womens & Childrens Hlth, Hematol Oncol Div, Via Giustiniani 3, I-35128 Padua, Italy

[2] Univ Washington, Seattle Childrens Hosp, Fred Hutchinson Canc Res Ctr, Div Hematol Oncol, Seattle, WA 98195 USA

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 05期

关键词：

chemotherapy duration; maintenance; rhabdomyosarcoma; soft tissue sarcoma; SOFT-TISSUE SARCOMA; LOW-RISK RHABDOMYOSARCOMA; INTERGROUP RHABDOMYOSARCOMA; NONMETASTATIC RHABDOMYOSARCOMA; INTERNATIONAL-SOCIETY; PEDIATRIC-ONCOLOGY; PROGNOSTIC-FACTORS; POOLED ANALYSIS; CHILDHOOD; ADOLESCENCE;

D O I：

10.1002/pbc.28174

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials have tested different chemotherapy regimens to improve outcome for patients with rhabdomyosarcoma (RMS), but therapy duration has never been explicitly evaluated. North American trials evolved from longer (104 weeks) to shorter duration (24-42 weeks). In Europe, treatment duration similarly evolved from 35 to 48 to 22 weeks for lower risk patients and from 56 to 72 to 27 weeks for higher risk patients. There was no evidence that chemotherapy duration influenced outcome over time. The recent RMS2005 trial showed an improved survival with the addition of 24 weeks of low-dose chemotherapy. Treatment duration remains a question to be addressed in future trials.

引用

页数：7

共 34 条

[1] Fifty years of rhabdomyosarcoma studies on both sides of the pond and lessons learned [J].

Arndt, Carola A. S. ;

Bisogno, Gianni ;

Koscielniak, Ewa .

CANCER TREATMENT REVIEWS, 2018, 68 :94-101

[2] Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803 [J].

Arndt, Carola A. S. ;

Stoner, Julie A. ;

Hawkins, Douglas S. ;

Rodeberg, David A. ;

Hayes-Jordan, Andrea A. ;

Paidas, Charles N. ;

Parham, David M. ;

Teot, Lisa A. ;

Wharam, Moody D. ;

Breneman, John C. ;

Donaldson, Sarah S. ;

Anderson, James R. ;

Meyer, William H. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5182-5188

[3] Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: Results from the Intergroup Rhabdomyosarcoma Study IV [J].

Baker, KS ;

Anderson, JR ;

Link, MP ;

Grier, HE ;

Qualman, SJ ;

Maurer, HM ;

Breneman, JC ;

Wiener, ES ;

Crist, WM .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2427-2434

[4] Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial [J].

Bisogno, Gianni ;

De Salvo, Gian Luca ;

Bergeron, Christophe ;

Gallego Melcon, Soledad ;

Merks, Johannes H. ;

Kelsey, Anna ;

Martelli, Helene ;

Minard-Colin, Veronique ;

Orbach, Daniel ;

Glosli, Heidi ;

Chisholm, Julia ;

Casanova, Michela ;

Zanetti, Ilaria ;

Devalck, Christine ;

Ben-Arush, Myriam ;

Mudry, Peter ;

Ferman, Sima ;

Jenney, Meriel ;

Ferrari, Andrea .

LANCET ONCOLOGY, 2019, 20 (11) :1566-1575

[5] Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial [J].

Bisogno, Gianni ;

Jenney, Meriel ;

Bergeron, Christophe ;

Gallego Melcon, Soledad ;

Ferrari, Andrea ;

Oberlin, Odile ;

Carli, Modesto ;

Stevens, Michael ;

Kelsey, Anna ;

De Paoli, Angela ;

Gaze, Mark N. ;

Martelli, Helene ;

Devalck, Christine ;

Merks, Johannes H. ;

Ben-Arush, Myriam ;

Glosli, Heidi ;

Chisholm, Julia ;

Orbach, Daniel ;

Minard-Colin, Veronique ;

De Salvo, Gian Luca .

LANCET ONCOLOGY, 2018, 19 (08) :1061-1071

[6] Long-term results in childhood rhabdomyosarcoma: A report from the Italian cooperative study RMS 79 [J].

Bisogno, Gianni ;

Pastore, Guido ;

Perilongo, Giorgio ;

Sotti, Guido ;

Cecchetto, Giovanni ;

Dallorso, Sandro ;

Carli, Modesto .

PEDIATRIC BLOOD & CANCER, 2012, 58 (06) :872-876

[7] Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group [J].

Casey, Dana L. ;

Chi, Yueh-Yun ;

Donaldson, Sarah S. ;

Hawkins, Douglas S. ;

Tian, Jing ;

Arndt, Carole A. ;

Rodeberg, David A. ;

Routh, Jonathan C. ;

Lautz, Timothy B. ;

Gupta, Abha A. ;

Yock, Torunn, I ;

Wolden, Suzanne L. .

CANCER, 2019, 125 (18) :3242-3248

[8] Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study) [J].

Chisholm, Julia C. ;

Merks, Johannes H. M. ;

Casanova, Michela ;

Bisogno, Gianni ;

Orbach, Daniel ;

Gentet, Jean-Claude ;

Thomassin-Defachelles, Anne-Sophie ;

Chastagner, Pascal ;

Lowis, Stephen ;

Ronghe, Milind ;

McHugh, Kieran ;

van Rijn, Rick R. ;

Hilton, Magalie ;

Bachir, Jeanette ;

Furst-Recktenwald, Sabine ;

Geoerger, Birgit ;

Oberlin, Odile .

EUROPEAN JOURNAL OF CANCER, 2017, 83 :177-184

[9] THE THIRD INTERGROUP RHABDOMYOSARCOMA STUDY [J].

CRIST, W ;

GEHAN, EA ;

RAGAB, AH ;

DICKMAN, PS ;

DONALDSON, SS ;

FRYER, C ;

HAMMOND, D ;

HAYS, DM ;

HERRMANN, J ;

HEYN, R ;

JONES, PM ;

LAWRENCE, W ;

NEWTON, W ;

ORTEGA, J ;

RANEY, RB ;

RUYMANN, FB ;

TEFFT, M ;

WEBBER, B ;

WIENER, E ;

WHARAM, M ;

VIETTI, TJ ;

MAURER, HM .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :610-630

[10] Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease [J].

Crist, WM ;

Anderson, JR ;

Meza, JL ;

Fryer, C ;

Raney, RB ;

Ruymann, FB ;

Breneman, J ;

Qualman, SJ ;

Wiener, E ;

Wharam, M ;

Lobe, T ;

Webber, B ;

Maurer, HM ;

Donaldson, SS .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) :3091-3102

← 1 2 3 4 →